Breaking Down The Multiple Sclerosis 2017 Formularies: 'Stability Fares Well For The Market'
Couldn't Make It To Leerink's Global Healthcare Conference? Here Are The Highlights From Day One
Biogen Optionality Looking Attractive; Bernstein Initiates At Outperform
Is Biogen Becoming A Reasonable Target For Acquisition? Baird Says So
Tecfidera Recent News
Why Leerink Is Cutting Biogen Targets (But Still Bullish On The Stock)
Market Update: Friday's Mid-Day Market Movers: Amazon Shocks The Markets; Anthem, Cigna, StanCorp, Pandora
Biogen's Final Catalyst Of 2015 Is A 'Coin Flip,' Evercore ISI Analyst Says
Piper Jaffray On Biogen Downgrade: '6 MG Data Does Not Inspire Confidence…Even More Speculative Than Before'
Nomura's Takeways From Biogen Idec's Analyst Meeting
Market Wrap For November 22: Markets Finish The Week On a Positive Note